Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities

Expert Review of Respiratory Medicine

Volumn 7, Issue 5, 2013, Pages 533-544

  Young, Robert P ^a   Hopkins, Raewyn J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

chronic obstructive pulmonary disease; co morbidities; HMG CoA reductase inhibitors; lung cancer; pneumonia, smokers; spirometry; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; ENDOTHELIAL DYSFUNCTION; INFLUENZA; LUNG CANCER; MORTALITY; PLEIOTROPY; PNEUMONIA; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS; COMORBIDITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886451653     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2013.838018     Document Type: Review

References (91)

1. Young RP, Hopkins RJ, Eaton TE. Forced expiratory volume in one second: Not just a lung function test but a marker of premature death from all causes. Eur. Resp. J. 30(4), 616-622 (2007
2. Janda S, Park K, Fitzgerald JM, Etminan M, Swiston J. Statins in COPD. Chest 136, 734-743 (2009
3. Young RP, Hopkins RJ, Eaton TE. Potential benefits of statins on morbidity and mortality in COPD: A review of the evidence. Postgrad. Med. J. 85, 414-421 (2009
4. Dobler CC, Wong KK, Marks GB. Association between statins and COPD: A systematic review. BMC Pulm. Med. 9, 32 (2009
5. Young RP, Hopkins RJ, Eaton TE. Pharmacological actions of statins: Potential utility in COPD. Eur Respir. Rev. 18, 222-232 (2009
6. Sin DD, Man PSF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107, 1514-1519 (2003
7. Barnes PJ, Celli BR. Systemic manifestations and co-morbidities in COPD. Eur. Respir. J. 33, 1165-1185 (2009
8. Agusti A, Edwards LD, Rennard SI et al. Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype. PLoS ONE 7(5), e37483 (2012
9. Cockayne DA, Cheng DT, Waschki B et al. Systemic Biomarkers of neutrophilic inflammation, tissue injury and repair in copd patients with differing levels of disease severity. PLoS ONE 7(6), e38629 (2012
10. Barr R-G. The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema. Proc. Am. Thorac. Soc. 8, 522-527 (2011
11. Fabbri LM, Beghe B, Agusti A. Cardiovascular mechanisms of death in severe COPD exacerbation: Time to think and act beyond guidelines. Thorax 66(9), 745-747 (2011
12. Walter RE, Wilk JB, Larsen MG et al. Systemic inflammation and COPD: The Framingham Heart Study. Chest 133, 19-25 (2008
13. Melbye H, Halvorsen DS, Hartz I et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Resp. Med. 101, 2541-2549 (2007
14. Boschetto P, Beghe B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. Respirology 17, 422-431 (2012
15. Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am. J. Cardiol. 101 530-535 (2008
16. Sin DD, Man SFP Interleukin 6. Chest 133, 4-6 (2008
17. Yende S, Waterer GW, Tolley EA et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 61, 10-16 (2006
18. Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur. Respir. J. 40, 724-741 (2012
19. Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD 9, 359-366 (2012
20. Hurst JR, Hagan G, Wedzicha JA. Mechanism of statin-Associated mortality reduction in COPD. Chest 132, 1409 (2007
21. Ahmad T, Mabalirajan U, Sharma A et al. Simvastatin improves epithelial dysfunction and airway hyperresponsiveness. From asymmetric dimethyl-Arginine to asthma. Am. J. Respir. Cell Mol. Biol. 44, 531-539 (2011
22. Sin DD, Anthonisen NR, Soriano JB, Augusti AG. Mortality in COPD: Role of co-morbidities. Eur. Respir. J. 28, 1245-57 (2006
23. Sinden NJ, Stockley RA. Systemic inflammation and co-morbidity in COPD: A result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 65, 930-936 (2010
24. Yanbeva DG, Detener MA, Creutzberg EC, Woulters EFM. Systemic inflammation in COPD: Is genetic susceptibility a key factor. COPD: 3, 51-61 (2006
25. Van Durme YMTA, Verhamme KMC, Aarnoudse A-JLHJ et al. C-Reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 179, 375-382 (2009
26. Tockman MS, Comstock GW. Respiratory risk factors and mortality: Longitudinal studies in Washington County, Maryland. Am. Rev. Respir. Dis. 140, S56-S63 (1989
27. Olofson J, Skoogh BE, Bake B, Svardsudd K. Mortality related to smoking habits, respiratory symptoms and lung function. Eur. J. Respir. Dis 71, 69-76 (1987
28. Rasmussen F, Mikkelsen D, Hancox RJ et al. High-sensitive C-reactive protein is associated with reduced lung function in adults. Eur. Respir. J. 33, 382-388 (2009
29. Gan WQ, Man SFP, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127, 558-564 (2005
30. Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 66, 764-768 (2011
31. Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V. Troponin T elevation and long-Term mortality after chronic obstructive pulmonary disease exacerbation. Eur. Respir. J. 31, 563-570 (2011
32. Hoiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Soyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 66, 775-781 (2011
33. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-Acquired pneumonia. Am. J. Med. 121, 219-225 (2008
34. Guertler C, Christ-Crain M, Zimmerli W, Mueller B, Scheutz P. Inflammatory responses predict long-Term mortality risk in community-Acquired pneumonia. Eur. Respir. J. 37, 1439-1446 (2011
35. Chang SS, Vaz Fragoso CA, Van Ness PH, Fried LP, Tinetti ME. Association between combined interleukin-6 and C-reactive protein levels and pulmonary function in older women; results from the Women's Health and Aging Studies I and II. J. Am. Geriatr. Soc. 59, 113-119 (2011
36. Siemes C, Visser LE, Coebergh J-W W et al. C-Reactive protein levels, variation in the C-Reactive protein gene, and cancer risk: The rotterdam study. J. Clin. Oncol. 24(33), 5216-5222 (2006
37. Cho WCS, Kwan CK, Yau S, So PPF, Poon PCM, Au JSK. The role of inflammation in the pathogenesis of lung cancer. Expert Opin. Ther. Targets 15(9), 1127-1137 (2011
38. Chaturvedi AK, Caporaso NE, Katki HA et al. C-Reactive protein and risk of lung cancer. J. Clin. Oncol. 28(16), 2719-2726 (2010
39. Nohria A, Prsic A, Liu PY et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205, 517-521 (2009
40. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 333 (7576), 999 (2006
41. Eurish DT, Majumdar SR. Statins and sepsis-scientifically interesting but clinically inconsequential. J Gen. Intern. Med. 27 (3), 268-269 (2011
42. Suissa S. Co-Morbidity in COPD: The effects of cardiovascular drug therapies. Respiration 80, 3-7 (2010
43. Lawes CMM, Thornley S, Young R, et al Statin use in COPD patients is associated with a reduction in mortality: A national cohort study. Prim. Care Respir. 21(1), 35-40 (2012
44. Lahousse L, Loth DW, Joos GF et al. Statins, systemic inflammation and risk of death in COPD: The Rotterdam study. Pulm. Pharmacol. Ther. 26(2), 212-217 (2012
45. Huang CC, Chan WL, Chen YC et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: A nationwide population-based cohort study in Taiwan. Clin. Ther. 33(10), 1365-1370 (2011
46. Bartziokas K, Papaioannou AI, Minas M et al. Statins and outcome after hospitalization for COPD exacerbation: A prospective study. Pulm. Pharmacol. Ther. 24, 625-631 (2011
47. Chopra V, Rogers MAM, Buits M et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-Analysis. Am. J. Med. 125, 1111-1123. (2012
48. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir. Med. 103, 224-229 (2009
49. Mendendez R, Martinez R, Reyes S et al. Biomarkers improve mortality prediction by prognostic scales in community-Acquired pneumonia. Thorax 64, 587-591(2009
50. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 250-255(2007
51. Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: Results from the JUPITER trial. CMAJ 184(7), E367-E372 (2012
52. Vandermeer ML, Thomas AR, Kamimoto L et al. Association between use of statins and mortality among patients hospitalised with laboratory-confirmed influenza virus infection: A multistate study. J. Infect. Dis. 205(1), 13-19 (2012
53. Young RP, Hopkins RJ. A clinical practice guideline update on the diagnosis and management of stable chronic obstructive pulmonary disease; comment. Ann. Int. Med. 156, 68-69 (2012
54. Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology 16, 1047-1055 (2011
55. Cohen BH, Diamond EL, Graves CVG et al. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 2(8037), 523-526 (1977
56. de Torres J, Bastarrika G, Wisnivesky JP et al. Assessing the relationship between lung cancer risk and emphysema detected on low dose CT of the chest. Chest 132, 1932-1938 (2007
57. Wilson DO, Weissfeld JL, Balkan A et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am. J. Respir. Crit. Care Med. 178, 738-744 (2008
58. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer independent of age, sex, and smoking history. Eur. Respir. J. 34, 380-386 (2009
59. Young RP, Hopkins RJ. Diagnosing COPD and targeted lung cancer screening. Eur. Respir. J. 40, 1063-1064 (2012
60. Young RP, Hopkins RJ, Whittington CF, Hay BA, Epton MJ, Gamble GD. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: Associations after sub-phenotyping for COPD. PLoS ONE 6, e16476 (2011
61. Young RP, Hopkins RJ. COPD and lung cancer linked at a molecular genetic level. Chest 140, 266-267 (2011
62. Yang IA, Relan V, Wright CM et al. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin. Ther. Targets 15(4), 439-456 (2011
63. Rooney C, Sethi T. The epithelial cell and lung cancer: The link between chronic obstructive pulmonary disease and lung cancer. Respiration 81, 89-104 (2011
64. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl J. Med. 367, 1792-1802 (2012
65. Young-Jin K, Young-Min K, Kyae HK et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol. Bio. Prev. 21, 2076-2086 (2012
66. Allin KH, Bojesen SE, Nordestgaard. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27 (13), 2217-2224 (2009
67. Iiyasova D, Colbert LH, Harris TB et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 14, 2413-2418 (2005
68. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11 (12), 886-895 (2011
69. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr. Pharma. Des. 18, 3831-3852 (2012
70. Agusti A, Faner R. Systemic inflammation and co-morbidities in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 9, 43-46 (2012
71. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 131, 1282-1288 (2007
72. Farwell WR, Scranton RE, Lawler EV et al. The association between statins and cancer incidence in a Veterans population. J. Natl Cancer Inst. 100, 134-139 (2008
73. Karp I, Behlouli H, LeLorier J, Pilote L. Statins and cancer risk. Am. J. Med. 121, 302-309 (2008
74. van Gestel YRBM, Hoeks SE, Sin DD et al. COPD and cancer mortality: The influence of statins. Thorax 64, 963-967 (2009
75. Young RP, Hopkins RJ. Effect of statins on cancer in chronic obstructive pulmonary disease. Thorax, 66, 354-355 (2011
76. Arimura K, Aoshiba K, Tsuji T, Tamaoki J. Chronic low-grade systemic inflammation causes DNA damage in the lungs of mice. Lung 190, 613-620 (2012
77. Ludman A, Venugopal V, Yellon DM, Hausenloy. Satins and cardioprotection-more than just lipid lowering. Pharmacol. Ther. 122, 30-43 (2009
78. Patti G, Cannon CP, Murphy SA et al. Clinical benefit of statin pre-Treatment in patients undergoing percutaneous coronary intervention: A collaborative patient-level meta-Analysis of 13 randomized studies. Circulation 123, 1622-1632 (2011
79. Strey CH, Young JM, Lainchbury JH et al. Short-Term statin therapy improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 92, 1603-1609 (2006
80. Young RP, Hopkins RJ. Possible role of statins in COPD-related pulmonary hypertension. Chest 137, 1250-1251 (2010
81. Shishehbor MH, Brennan ML, Aviles RJ et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108, 426-431 (2003
82. Young RP, Hopkins RJ. Statins in small airways disease in COPD. Am. J. Resp. Mol. Cell. Biol. 49(3), 501 (2013
83. Arnaud C, Burger F, Steffens S et al. Statins reduce interleukin-6- induced C-reactive protein in human hepatocytes: New evidence for direct anti-inflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 25, 1231-1236 (2005
84. Groenewegen KH, Postma DS, Hop WCJ et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 133, 350-357 (2008
85. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186, 982-988 (2012
86. Ferrari R, Tanni SE, Caram LMO, Correa C, Correa CR, Godoy I. Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir. Res. 14, 24-30 (2013
87. Thomsen M, Ingebrigtsen TS, Marott JL et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 309, 2353-2361 (2013
88. Wang MT, Lo YW, Tsai CL et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 126, 598-606.e2 (2013
89. McDonald V M, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: Respiratory utopia or common sense?Thorax 68, 691-694 (2013
90. Agusti A, MacNee W. The COPD control panel: Towards personalized medicine in COPD. Thorax 68, 687-690 (2013
91. Young RP, Hopkins RJ. Interleukin-6 and statin therapy: Potential role in the management of COPD. Respir. Res. 14, 74-75(2013